Splash Beverage entered a Development and Collaboration Agreement with Lupvindol to lead FDA regulatory work for a cannabinoid-based veterinary drug derived from CannEpil. The plan covers INAD initiation, studies, and filing for conditional approval, with Splash funding milestones totaling up to $1.11 million and, upon approval or licensing, a 4% net sales royalty (or Lupvindol may elect Splash common stock instead). The initial term is five years with automatic one-year renewals, and includes customary termination rights.
Agreement details:
- Agreement type: Development and Collaboration Agreement for veterinary drug development and FDA conditional approval
- Counterparty: Lupvindol Biosciences
- Signed / Effective: Jul 31 2026 / Jul 31 2026
- Duration / Termination: 5 years initial, auto-renews yearly
- Reason: Advance CannEpil into U.S. veterinary market via FDA conditional approval
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.